Vietnam Accused Of Failing To Follow Law On Drug Import Pricing
This article was originally published in PharmAsia News
Executive Summary
Vietnam's regulation of imported drugs is suffering from lax management by the agencies responsible, leading to recent increases in the price of medicine. One of the core problems, according to the Ho Chi Minh City Health Department's deputy director, lies in the Drug Administration of Vietnam's failure to put wholesale and retail prices on its public list. The law requires drug importers to consider the cost, insurance and freight in determining the two types of prices submitted to the DAV. Deputy Director Pham Khanh Phong Lan said the agency lists only the overall CIF prices and does not break out the wholesale and retail prices as required. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.